SCHEMBL5879808

SCHEMBL5879808

NN=Cc1ccccc1OS(=O)(=O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.53
MAPK1 P28482 1/20 0.53
ALDH1A1 P00352 5/20 0.51
MAPT P10636 4/20 0.51
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
HTT P42858 2/20 0.48
GAA P10253 2/20 0.44
HSD11B1 P28845 1/20 0.44
HSD17B3 P37058 1/20 0.44
KDM4E B2RXH2 1/20 0.42
PTGS2 P35354 2/20 0.40
PTGS1 P23219 1/20 0.40
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
KIF11 P52732 1/20 0.39
ENPP3 O14638 1/20 0.38
ENPP1 P22413 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879803 1.00 LMNA (0.53) LMNAMAPK1ALDH1A1MAPTMEN1
SCHEMBL5880350 1.00 LMNA (0.53) LMNAMAPK1ALDH1A1MAPTMEN1
SCHEMBL5879641 0.85 ALDH1A1 (0.69) LMNAMAPK1ALDH1A1MAPTMEN1
SCHEMBL5879760 0.83 ALDH1A1 (0.51) LMNAMAPK1ALDH1A1MAPTMEN1
SCHEMBL5880124 0.82 MAPT (0.58) LMNAMAPK1ALDH1A1MAPTMEN1
SCHEMBL5879609 0.82 GAA (0.53) LMNAMAPK1ALDH1A1MAPTMEN1
SCHEMBL5879610 0.82 GAA (0.53) LMNAMAPK1ALDH1A1MAPTMEN1
SCHEMBL5880128 0.82 MAPT (0.58) LMNAMAPK1ALDH1A1MAPTMEN1
SCHEMBL5880042 0.79 LMNA (0.45) LMNAMAPK1ALDH1A1MAPTMEN1
SCHEMBL5880048 0.79 LMNA (0.45) LMNAMAPK1ALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026339-B2 Inhibitors of HCV NS5B polymerase PFIZER INC. 2006-04-11 US disclosed
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate PHARMACIA & UPJOHN COMPANY 2005-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate ACACB, HCCS, HAVCR2 LMNA 4281/4885MAPK1 3992/4885ALDH1A1 1095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.